Supplementary table 2. USF1 SNPs and haplotypes and their association with SP type and NFT prevalence (APOE4 carriership and age as covariates) in males.

	rs10908821				rs2073658				rs2774276				rs2516839				rs1556259				rs2774279			
	Aff. (%) CC*/G+	OR	CI	*p*	Aff. (%) CC*/T+	OR	CI	*p*	Aff. (%) CC*/G+	OR	CI	*p*	Aff. (%) TT*/C+	OR	CI	*p*	Aff. (%) AA*/G+	OR	CI	*p*	Aff. (%) CC*/T+	OR	CI	*p*
SP	56(22.7)/24(27.9)	1.12	0.60-2.09	NS	30(22.7)/50(24.9)	1.15	0.65-2.04	NS	43(23.1)/38(25.3)	1.13	0.65-1.97	NS	28(23.1)/52(24.4)	1.02	0.57-1.82	NS	59(24.2)/21(23.3)	0.97	0.51-1.84	NS	50(25.9)/30(21.4)	0.73	0.41-2.30	NS
Non neuritic	18(7.3)/9(10.7)	1.33	0.59-3.17	NS	12(9.2)/16(8.1)	1.02	0.46-2.28	NS	9(4.9)/19(12.9)	2.53	1.09-5.88	0.030	5(4.1)/22(10.5)	2.44	0.88-6.73	NS	20(8.3)/8(9.0)	1.11	0.46-2.68	NS	19(10.0)/8(5.8)	0.49	0.20-1.18	NS
Neuritic	39(15.9)/11(13.1)	0.58	0.25-1.32	NS	15(11.5)/34(17.2)	1.71	0.83-3.53	NS	34(18.4)/16(10.9)	0.54	0.26-1.11	NS	23(19.0)/27(12.9)	0.60	0.30-1.20	NS	36(14.9)/13(14.6)	1.04	0.48-2.27	NS	31(16.3)/19(13.7)	0.69	0.34-1.37	NS
Diffuse	9(3.7)/2(2.4)	0.61	0.13-2.95	NS	5(3.8)/7(3.5)	1.07	0.33-3.50	NS	3(1.6)/9(6.1)	3.64	0.96-13.9	0.058	2(1.7)/9(4.3)	2.50	0.53-11.9	NS	9(3.7)/3(3.4)	0.91	0.24-3.51	NS	7(3.7)/4(2.9)	0.68	0.19-2.40	NS
Primitive	9(3.7)/7(8.3)	2.02	0.71-5.77	NS	7(5.3)/9(4.5)	0.98	0.35-2.77	NS	6(3.2)/10(6.8)	1.99	0.69-5.70	NS	3(2.5)/13(6.2)	2.41	0.66-8.76	NS	11(4.6)/5(5.6)	1.29	0.42-3.90	NS	12(6.3)/4(2.9)	0.38	0.12-1.24	NS
Classic	27(11.0)/9(10.7)	0.70	0.28-1.71	NS	10(7.6)/26(13.1)	1.99	0.87-4.56	NS	24(13.0)/13(8.8)	0.61	0.28-1.34	NS	15(12.4)/21(10.0)	0.72	0.33-1.55	NS	25(10.4)/11(12.4)	1.26	0.55-2.92	NS	24(12.6)/12(8.6)	0.56	0.35-1.24	NS
Burnt out	12(4.9)/2(2.4)	0.32	0.06-1.60	NS	5(3.8)/8(4.0)	1.15	0.35-3.82	NS	10(5.4)/3(2.0)	0.35	0.09-1.38	NS	8(6.6)/6(2.9)	0.38	0.12-1.22	NS	11(4.6)/2(2.2)	0.52	0.11-2.55	NS	7(3.7)/7(5.0)	1.12	0.36-3.46	NS
Cerad ≤1.5%	34(13.8)/10(11.6)	0.82	0.37-1.82	NS	16(12.1)/29(14.4)	1.28	0.64-2.56	NS	24(12.9)/21(14.0)	1.11	0.57-2.15	NS	15(12.4)/29(13.6)	1.08	0.53-2.18	NS	31(12.7)/14(15.6)	1.21	0.59-2.51	NS	29(15.0)/15(10.7)	0.63	0.31-1.28	NS
Cerad >1.5%	22(8.9)/14(16.3)	1.62	0.72-3.65	NS	14(10.6)/21(10.4)	0.97	0.44-2.15	NS	19(10.2)/17(11.3)	1.19	0.55-2.58	NS	13(10.7)/23(10.8)	0.94	0.42-2.08	NS	28(11.5)/7(7.8)	0.64	0.24-1.67	NS	21(10.9)/15(10.7)	0.89	0.41-1.94	NS
NFT	74(34.9)/26(36.1)	0.80	0.43-1.49	NS	41(35.0)/59(35.1)	1.06	0.61-1.83	NS	56(35.9)/46(34.8)	0.91	0.53-1.57	NS	34(35.1)/66(35.1)	1.05	0.60-1.87	NS	72(34.8)/28(35.4)	1.16	0.63-2.13	NS	53(32.1)/47(39.5)	1.39	0.80-2.40	NS

	Haplotype 2 (CCCTAT)				Haplotype 3 (CCCCGC)				Haplotype 4 (CCGCAC)				Haplotype 5 (CTCTAC)				Haplotype 7 (GCGCAC)			
	Aff. (%) H2-*/H2+	OR	CI	*p*	Aff. (%) H3-*/H3+	OR	CI	*p*	Aff. (%) H4-*/H4+	OR	CI	*p*	Aff. (%) H5-*/H5+	OR	CI	*p*	Aff. (%) H7-*/H7+	OR	CI	*p*
SP	56(27.5)/30(21.1)	0.68	0.39-1.19	NS	64(25.2)/22(23.9)	0.99	0.52-1.85	NS	70(25.8)/16(21.3)	0.85	0.44-1.66	NS	32(23.4)/54(25.8)	1.16	0.66-2.02	NS	60(23.5)/26(28.6)	1.18	0.64-2.16	NS
Non neuritic	23(10.6)/8(5.7)	0.44	0.19-1.03	NS	23(8.6)/8(8.8)	1.04	0.44-2.48	NS	21(7.4)/10(13.5)	1.75	0.76-4.00	NS	12(8.8)/19(8.6)	1.15	0.53-2.52	NS	21(7.8)/10(11.2)	1.32	0.58-3.00	NS
Neuritic	35(16.2)/19(13.5)	0.68	0.34-1.32	NS	40(15.0)/14(15.4)	1.13	0.53-2.39	NS	47(16.6)/7(9.5)	0.64	0.26-1.56	NS	17(12.5)/37(16.7)	1.53	0.77-3.04	NS	42(15.7)/12(13.5)	0.66	0.30-1.45	NS
Diffuse	10(4.6)/4(2.8)	0.51	0.15-1.69	NS	11(4.1)/3(3.3)	0.80	0.22-3.00	NS	8(2.8)/6(8.1)	2.72	0.89-8.29	NS	5(3.7)/9(4.1)	1.31	0.42-4.07	NS	11(4.1)/3(3.4)	0.77	0.20-2.88	NS
Primitive	13(6.0)/4(2.8)	0.38	0.12-1.23	NS	12(4.5)/5(5.5)	1.26	0.42-3.78	NS	13(4.6)/4(5.4)	1.14	0.35-3.68	NS	7(5.1)/10(4.5)	1.04	0.38-2.87	NS	10(3.7)/7(7.9)	1.91	0.68-5.31	NS
Classic	28(13.0)/12(8.5)	0.54	0.25-1.17	NS	29(10.9)/11(12.1)	1.23	0.54-2.78	NS	36(12.7)/4(5.4)	0.47	0.15-1.42	NS	11(8.1)/29(13.1)	1.85	0.84-4.06	NS	30(11.2)/10(11.2)	0.80	0.34-1.85	NS
Burnt out	7(3.2)/7(5.0)	1.22	0.39-3.76	NS	11(4.1)/3(3.3)	0.85	0.22-3.35	NS	11(3.9)/3(4.1)	1.25	0.32-4.93	NS	6(4.4)/8(3.6)	0.93	0.30-2.90	NS	12(4.5)/2(2.2)	0.35	0.07-1.71	NS
Cerad ≤1.5%	32(15.8)/15(10.6)	0.58	0.29-1.16	NS	33(13.0)/14(15.2)	1.17	0.57-2.41	NS	35(13.0)/12(16.0)	1.17	0.55-2.48	NS	16(11.7)/31(14.9)	1.38	0.70-2.73	NS	36(14.2)/11(12.1)	0.86	0.40-1.85	NS
Cerad >1.5%	23(11.3)/15(10.6)	0.86	0.40-1.86	NS	30(11.9)/8(8.7)	0.73	0.29-1.85	NS	34(12.6)/4(5.3)	0.48	0.15-1.47	NS	16(11.7)/22(10.6)	0.87	0.40-1.87	NS	23(9.1)/15(16.5)	1.78	0.80-3.96	NS
NFT	62(33.0)/47(38.8)	1.32	0.78-2.23	NS	80(35.1)/29(35.8)	1.19	0.66-2.14	NS	88(36.8)/21(30.0)	0.76	0.41-1.41	NS	44(36.1)/65(34.8)	0.98	0.58-1.66	NS	80(34.5)/29(37.7)	0.96	0.53-1.73	NS

*denotes the most common haplotype/homozygous genotype acting as the reference group in the analyses. Aff.(%) refers to number of individuals affected with SP/NFT.

USF1 − upstream transcription factor 1 gene, SNPs − single nucleotide polymorphisms, SP − senile plaques, NFT − neurofibrillary tangles, APOE4 − Apolipoprotein E ε4, OR − odds ratio, CI − confidence interval, *p* − p-value, NS − non significant p-value